Phase 1 Study of Anti-glycation Agent GLY-230 in Healthy Subjects

Phase 1 Study of Anti-glycation Agent GLY-230

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00544921

Enrollment

Registered

2007-10-16

Start date

2005-10-31

Completion date

2006-10-31

Last updated

2016-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Brief summary

To test the safety of GLY-230 and to evaluate how long drug stays in blood after taking it by mouth.

Interventions

OTHERPlacebo

No drug administered

DRUGGLY-230

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

18 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

* Men age 18-55 * Negative drug screen * Normal EKG, clinical chemistries, CBC, urinalysis, and * Give written informed consent

Exclusion criteria

* Active concomitant serious medical or surgical disease, * Hepatic or renal laboratory values above reference range, ise of other experimental drug within previous 30 days

Design outcomes

Primary

Measure	Time frame
A Dose-Ranging Study to Evaluate the Phamacokinetics and Safety of Six Single-Dose Levels of GLY-230 in Healthy Subjects	October, 2005 to October, 2006

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026